• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Dis. A Novel Strain of Clostridium botulinum That Produces Type B and Type H Botulinum Toxins

Giuseppe

Emeritus
[Source: Journal of Infectious Diseases, full page: (LINK). Abstract, edited.]


A Novel Strain of Clostridium botulinum That Produces Type B and Type H Botulinum Toxins

Jason R. Barash and Stephen S. Arnon

Author Affiliations: Infant Botulism Treatment and Prevention Program, California Department of Public Health, Richmond, California

Correspondence: Stephen S. Arnon, MD, Infant Botulism Treatment and Prevention Program, California Department of Public Health, 850 Marina Bay Pkwy, Rm E-361, Richmond, CA 94804 (stephen.arnon@cdph.ca.gov).


Abstract

Background.

Clostridium botulinum strain IBCA10-7060, isolated from a patient with infant botulism, produced botulinum neurotoxin type B (BoNT/B) and another BoNT that, by use of the standard mouse bioassay, could not be neutralized by any of the Centers for Disease Control and Prevention?provided monovalent polyclonal botulinum antitoxins raised against BoNT types A?G.


Methods and Results.

The combining of antitoxins to neutralize the toxicity of known bivalent C. botulinum strains Ab, Ba, Af, and Bf also failed to neutralize the second BoNT. Analysis of culture filtrate by double immunodiffusion yielded a single line of immunoprecipitate with anti-A, anti-B, and anti-F botulinum antitoxins but not with anti-E antitoxin. A heptavalent F(ab?)<SUB>2</SUB> botulinum antitoxin A?G obtained from the US Army also did not neutralize the second BoNT. An antitoxin raised against IBCA10-7060 toxoid protected mice against BoNT/B (Okra) and against the second BoNT but did not protect mice against BoNT/A (Hall) or BoNT/F (Langeland).


Conclusions.

The second BoNT thus fulfilled classic criteria for being designated BoNT/H. IBCA10-7060 is the first C. botulinum type Bh strain to be identified. BoNT/H is the first new botulinum toxin type to be recognized in >40 years, and its recognition could not have been accomplished without the availability of the mouse bioassay.


Key words: botulinum toxin ? botulism - Clostridium botulinum - botulinum antitoxin - mouse bioassay

Received May 17, 2013. Accepted August 5, 2013.

? The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.

For Permissions, please e-mail: journals.permissions@oup.com.

-
-------
 
Back
Top Bottom